These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37520706)

  • 1. Flexible thin film thermocouples: From structure, material, fabrication to application.
    Zhang Z; Liu Z; Lei J; Chen L; Li L; Zhao N; Fang X; Ruan Y; Tian B; Zhao L
    iScience; 2023 Aug; 26(8):107303. PubMed ID: 37520735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and function of a novel human memory-like NK cell population expressing CD160 in melioidosis.
    Preechanukul A; Kronsteiner B; Saiprom N; Rochaikun K; Moonmueangsan B; Phunpang R; Ottiwet O; Kongphrai Y; Wapee S; Chotivanich K; Morakot C; Janon R; Dunachie SJ; Chantratita N
    iScience; 2023 Aug; 26(8):107234. PubMed ID: 37520720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration.
    Wu DD; Salah YA; Ngowi EE; Zhang YX; Khattak S; Khan NH; Wang Y; Li T; Guo ZH; Wang YM; Ji XY
    iScience; 2023 Aug; 26(8):107321. PubMed ID: 37554468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging-guided companion diagnostics in radiotherapy by monitoring APE1 activity with afterglow and MRI imaging.
    Yue R; Li Z; Liu H; Wang Y; Li Y; Yin R; Yin B; Qian H; Kang H; Zhang X; Song G
    Nat Commun; 2024 Jul; 15(1):6349. PubMed ID: 39068156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.
    Kontoghiorghes GJ
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging biomedical imaging-based companion diagnostics for precision medicine.
    Liao S; Zhou M; Wang Y; Lu C; Yin B; Zhang Y; Liu H; Yin X; Song G
    iScience; 2023 Aug; 26(8):107277. PubMed ID: 37520706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein array-based companion diagnostics in precision medicine.
    Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
    Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
    Front Oncol; 2014; 4():58. PubMed ID: 24744988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics.
    Zhong X; Guo J; Han X; Wu W; Yang R; Zhang J; Shao G
    Mol Pharm; 2023 May; 20(5):2402-2414. PubMed ID: 37015025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly Sensitive Imaging of Tumor Metastasis Based on the Targeting and Polarization of M2-like Macrophages.
    Yuan P; Xu X; Hu D; Chen Y; Fan J; Yao S; Piao Y; Zhou Z; Shao S; Slater NKH; Shen Y; Tang J
    J Am Chem Soc; 2023 Apr; 145(14):7941-7951. PubMed ID: 36987634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Scalable Platform for Fabricating Biodegradable Microparticles with Pulsatile Drug Release.
    Graf TP; Qiu SY; Varshney D; Laracuente ML; Euliano EM; Munnangi P; Pogostin BH; Baryakova T; Garyali A; McHugh KJ
    Adv Mater; 2023 Jun; 35(22):e2300228. PubMed ID: 36862114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).
    Wang Q; Zeng A; Zhu M; Song L
    Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36601768
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.